Cargando…

Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial

Detalles Bibliográficos
Autores principales:	Parra-Lara, Luis Gabriel, Martinez-Arboleda, Juan José, Isaza-Pierotti, Daniel Francisco, Rosso, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779262/ https://www.ncbi.nlm.nih.gov/pubmed/33408017 http://dx.doi.org/10.1016/j.ijantimicag.2020.106172

Ejemplares similares

Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
por: Gautret, Philippe, et al.
Publicado: (2021)

Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
por: dos Santos, Marcelo Rodrigues
Publicado: (2021)

Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
por: Saad, Mohamed O
Publicado: (2021)

Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
por: Wambier, Carlos Gustavo
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
por: Gautret, Philippe, et al.
Publicado: (2021)

Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
por: Parra-Lara, Luis Gabriel, et al.
Publicado: (2020)

An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results
por: Ader, Florence
Publicado: (2022)

Fixed Drug Eruption to Hydroxychloroquine
por: Swarnkar, Bhavya, et al.
Publicado: (2021)

Update on hydroxychloroquine use in pregnancy
por: Nori, Wassan, et al.
Publicado: (2023)

Thrombotic microangiopathy: COVID-19 or hydroxychloroquine?
por: Hasbal, Nuri Baris
Publicado: (2020)

Hydroxychloroquine-Associated Thrombotic Thrombocytopenic Purpura
por: Arıkan, Fatma, et al.
Publicado: (2020)

Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Hydroxychloroquine: is there a role in long COVID?
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Hydroxychloroquine for the management of chronic chikungunya arthritis
por: Nogueira, Igor Albuquerque, et al.
Publicado: (2023)

In Response: Dexmedetomidine versus propofol in dilatation and curettage: An open-label pilot randomized controlled trial
por: Tomar, GS
Publicado: (2016)

An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation
por: Yetkin, E., et al.
Publicado: (2020)

Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic()
por: Jáuregui, Edwin
Publicado: (2021)

Hydroxychloroquine (HCQ): real treatment or false hope?
por: El Bakkouri, Karim
Publicado: (2021)

Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients
por: Mahmoudi, Javad, et al.
Publicado: (2021)

Letter to the editor: The effect of hydroxychloroquine on COVID-19
por: Demir, Canan, et al.
Publicado: (2022)

Analysis of hydroxychloroquine prescriptions for COVID‐19 in Japan
por: Watari, Takashi, et al.
Publicado: (2023)

Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?
por: Elavarasi, Arunmozhimaran, et al.
Publicado: (2020)

Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19
por: Gevers, S., et al.
Publicado: (2020)

Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients
por: Rani, Seema, et al.
Publicado: (2020)

The Effect of Hydroxychloroquine on Cardiovascular Disease in Patients with Rheumatoid Arthritis
por: Mo, De-Gang, et al.
Publicado: (2022)

The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19
por: Sadasivam, Balakrishnan, et al.
Publicado: (2020)

Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment
por: Carbillon, Lionel, et al.
Publicado: (2021)

Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
por: Emmanuel, Stip, et al.
Publicado: (2020)

Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health-care workers
por: Simova, I., et al.
Publicado: (2020)

COVID-19 and hydroxychloroquine: Let the available data speak for themselves
por: Paliani, Ugo, et al.
Publicado: (2020)

Can we use hydroxychloroquine to treat COVID-19 now?
por: Chen, Jun, et al.
Publicado: (2021)

Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19
por: Kulkarni, Chanda, et al.
Publicado: (2021)

Hydroxychloroquine Reduces Proteinuria in Indian Patients With IgA Nephropathy
por: Bagchi, Soumita, et al.
Publicado: (2022)

Hydroxychloroquine-Induced Reversible Hypomnesis in a Patient with Reticular Erythematous Mucinosis
por: Lin, Qing, et al.
Publicado: (2012)

Letter to the Editor: Acharya Prafulla Chandra Ray, Hydroxychloroquine and COVID-19
por: Gupta, Nikhil, et al.
Publicado: (2020)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients
por: Brito-Azevedo, Anderson
Publicado: (2020)

Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19
por: Yang, Alexander, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4feemq5fhh36eo72mb4ob25dlj